NOVORAPID 100 UNIT
INSULIN ASPART : 100 UNIT · DIN 02377209 · NOVO NORDISK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is NOVORAPID?
NOVORAPID 100 UNIT contains INSULIN ASPART : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02377209, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 16-Aug-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NOVORAPID used for?
Treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02377209 |
|---|---|
| Brand name | NOVORAPID |
| Generic / active ingredient | INSULIN ASPART : 100 UNIT |
| Manufacturer | NOVO NORDISK CANADA INC |
| Strength | 100 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AB05 INSULIN ASPART |
| AHFS class | 68:20.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 16-Aug-2023 |
| Original market date | 2012-05-04 00:00:00 |
How is it administered?
Individualized dose (usually 0.5-1.0 units/kg/day). Administer SC 5-10 min before or immediately after a meal. Rotate injection sites. Can be used in CSII pump systems (10 mL vials).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to section 11), but standard insulin storage usually applies.
How is it supplied?
10 mL vials, 3 mL Penfill cartridges, and NovoRapid FlexTouch disposable pens. Pack sizes: 1 x 10 mL (vial), 1 x 3 mL, and 5 x 3 mL (others).
Contraindications
During episodes of hypoglycemia; patients who are hypersensitive to this drug or to any ingredient in the formulation.
Warnings and precautions
Hypoglycemia risk; uncorrected reactions can be fatal. Rapid onset requires immediate meal. Do not share devices. Risk of hypokalemia. Check labels to avoid medication errors.
What can be used instead?
Other Canadian products sharing ATC code A10AB05 INSULIN ASPART. 8 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02460408 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02460416 |
| KIRSTY | 100 UNIT | SOLUTION | BIOCON SDN.BHD | MARKETED | DIN 02520974 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02245397 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02244353 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02529254 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02506564 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02506572 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | DIN 02460424 |
| KIRSTY | 100 UNIT | SOLUTION | BIOCON SDN.BHD | APPROVED | DIN 02520982 |
Who else supplies INSULIN ASPART worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN ASPART appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.